



Ventripoint Diagnostics Issues Shares in Payment of Debenture Interest, Consulting Fees and DSU Exercise

Toronto, Ontario – The Newswire – November 26, 2020 - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) announces it will issue an aggregate of 233,365 shares for the payment of \$23,337 of interest for the three months ended November 6, 2020, on Convertible Debentures issued by the Corporation on February 6, 2020 and Convertible Debentures issued the same date as part of a replacement of convertible debentures. Pursuant to the Convertible Debentures, the shares will be issued at a deemed price of \$0.10 per share. Two Directors of the Company will receive a total of 72,523 common shares in payment of \$4,085 of interest on their Convertible Debentures.

The Company will also issue an aggregate of 554,666 shares to two consultants for \$41,600 in consulting fees at a deemed price of \$0.075 per share.

In addition, 142,500 shares will be issued pursuant to the exercise of Deferred Share Units, issued under the Company's DSU Plan, by a retired director, at a deemed price of \$0.10 per share.

All the above issuances of shares are subject to the approval of the TSXV Exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams
Email: gadams@ventripoint.com
Phone: 519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.